PBS’ Resolve to Solve highlights WVU Rockefeller Neuroscience Institute’s focused ultrasound research for addiction and a broader challenge for the field: making non-invasive brain therapy more practical, accessible, and scalable.
The Focused Ultrasound Foundation featured NaviFUS’ recent Epilepsia publication on non-invasive focused ultrasound neuromodulation for drug-resistant epilepsy, highlighting the study’s clinical significance and continued development of the field.
Focused ultrasound is opening new possibilities for how we reach and interact with the brain — without traditional surgery.
In a recent feature, WIRED explored the work of Dr. Ali Rezai and the WVU Rockefeller Neuroscience Institute (RNI), highlighting the evolving role of focused ultrasound in neurological and behavioral research.
NaviFUS Corporation announced the online publication of “Low-intensity focused ultrasound neuromodulation for drug-resistant epilepsy: A randomized, sham-controlled crossover trial.” Conducted at Taipei Veterans General Hospital, the pilot, single-blind study enrolled 12 adults with drug-resistant epilepsy. Each participant completed both low-intensity focused ultrasound (LIFU) and sham treatment, allowing the study to evaluate individualized targeting, preliminary safety, clinical feasibility, and efficacy signals.
Children’s National Hospital is advancing new possibilities in pediatric brain tumor care through expanded focused ultrasound research using the NaviFUS neuronavigation-guided low-intensity focused ultrasound (LIFU) platform. The collaboration supports ongoing efforts to explore non-invasive therapeutic approaches for children with difficult-to-treat brain tumors.
Key Points：
-Researchers in Taiwan completed an early-stage trial showing focused ultrasound–mediated blood-brain barrier opening plus chemotherapy is safe in patients with GBM.
– The investigators are now recruiting participants for a larger clinical trial with the same device – the NaviFUS system – at two sites.
Taipei, Taiwan – November 25, 2025 – At the 8th Asian–Oceanian Congress of Clinical Neurophysiology (AOCCN 2025) in Taipei, NaviFUS Corp. (6872) announced encouraging early clinical data showing that its neuronavigation-guided focused ultrasound (FUS) system is expanding beyond epilepsy into the field of stroke rehabilitation.
Genovate Biotechnology and NaviFUS Corporation have completed the first cohort of an investigator-initiated pilot study at Alfred Hospital in Australia, using the NaviFUS neuronavigation-guided focused ultrasound system in patients with drug-resistant epilepsy (DRE).
An independent Safety Monitoring Committee confirmed a favorable safety profile with no major safety concerns and recommended moving to the next cohort with additional treatment sessions.
Early results are encouraging, with most participants showing fewer seizure days and lower seizure frequency, including some with >80% reduction from baseline.
NaviFUS Corps. (6872) announced that the U.S. clinical trial of its NaviFUS® focused ultrasound system for drug-resistant epilepsy (DRE), led by Stanford University successfully completed treatment of its first patient at the middle of Aug. The trial is expected to finish enrollment of all six participants in the first half of next year.
Key Points:
-The study is testing NaviFUS’s neuronavigation-guided focused ultrasound system for treating patients with drug-resistant epilepsy.
-Up to 18 participants will be treated in Melbourne.
